WallStreetZenWallStreetZen

NASDAQ: MPLT
Maplight Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MPLT

Based on 4 analysts offering 12 month price targets for Maplight Therapeutics Inc

Min Forecast
$28.00+58.28%
Avg Forecast
$31.00+75.24%
Max Forecast
$34.00+92.2%

Should I buy or sell MPLT stock?

Based on 4 analysts offering ratings for Maplight Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MPLT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MPLT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MPLT stock forecasts and price targets.

MPLT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-21
lockedlocked$00.00+00.00%2025-11-21
lockedlocked$00.00+00.00%2025-11-21
lockedlocked$00.00+00.00%2025-11-21

1 of 1

Forecast return on equity

Is MPLT forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is MPLT forecast to generate an efficient return on assets?

Company
-68.46%
Industry
27.89%
MPLT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MPLT earnings per share forecast

What is MPLT's earnings per share in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$3.77
Avg 2 year Forecast
-$3.88

MPLT revenue forecast

What is MPLT's revenue in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

MPLT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MPLT$17.69$31.00+75.24%Strong Buy
ABUS$4.13$5.00+21.07%Strong Buy
KALV$15.61$33.33+113.54%Buy
JANX$13.71$56.63+313.02%Strong Buy
GYRE$8.09$17.00+110.14%Strong Buy
View Top Biotech Stocks

Maplight Therapeutics Stock Forecast FAQ

Is Maplight Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: MPLT) stock is to Strong Buy MPLT stock.

Out of 4 analysts, 3 (75%) are recommending MPLT as a Strong Buy, 1 (25%) are recommending MPLT as a Buy, 0 (0%) are recommending MPLT as a Hold, 0 (0%) are recommending MPLT as a Sell, and 0 (0%) are recommending MPLT as a Strong Sell.

If you're new to stock investing, here's how to buy Maplight Therapeutics stock.

What is MPLT's earnings growth forecast for 2026-2027?

(NASDAQ: MPLT) Maplight Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 202.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,205.53%.

Maplight Therapeutics's earnings in 2026 is N/A.On average, 6 Wall Street analysts forecast MPLT's earnings for 2026 to be -$170,892,991, with the lowest MPLT earnings forecast at -$195,648,518, and the highest MPLT earnings forecast at -$132,443,883.

In 2027, MPLT is forecast to generate -$176,097,278 in earnings, with the lowest earnings forecast at -$222,327,862 and the highest earnings forecast at -$121,486,296.

What is MPLT's revenue growth forecast for 2026-2027?

(NASDAQ: MPLT) Maplight Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 12,155.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,548.38%.

Maplight Therapeutics's revenue in 2026 is N/A.On average, 6 Wall Street analysts forecast MPLT's revenue for 2026 to be $0, with the lowest MPLT revenue forecast at $0, and the highest MPLT revenue forecast at $0.

In 2027, MPLT is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is MPLT's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: MPLT) forecast ROA is -68.46%, which is lower than the forecast US Biotechnology industry average of 27.89%.

What is MPLT's Price Target?

According to 4 Wall Street analysts that have issued a 1 year MPLT price target, the average MPLT price target is $31.00, with the highest MPLT stock price forecast at $34.00 and the lowest MPLT stock price forecast at $28.00.

On average, Wall Street analysts predict that Maplight Therapeutics's share price could reach $31.00 by Nov 21, 2026. The average Maplight Therapeutics stock price prediction forecasts a potential upside of 75.24% from the current MPLT share price of $17.69.

What is MPLT's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: MPLT) Maplight Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that MPLT's EPS will be -$3.77 for 2026, with the lowest EPS forecast at -$4.31, and the highest EPS forecast at -$2.92. In 2027, MPLT's EPS is forecast to hit -$3.88 (min: -$4.90, max: -$2.68).

What is MPLT's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: MPLT) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.